DBP International

Double Bond Pharmaceutical International AB is a Swedish biopharmaceutical company focused on developing innovative treatments for orphan diseases, with a primary emphasis on oncology. The company utilizes its proprietary BeloGal platform technology to enhance the delivery of existing active pharmaceutical ingredients to specific organs, thereby improving efficacy and reducing systemic toxicity. Its lead candidate, SI-053 (Temozolomide gel), is being developed for the local treatment of glioblastoma multiforme and is currently in clinical trials. DBP also maintains a pipeline of products targeting liver and lung cancers through its organ-specific delivery approach. Additionally, the company operates a subsidiary, Drugsson AB, which handles the distribution of pharmaceutical products in the Nordic market.